Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • Florida
  • Jacksonville


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • IVM With Low Cost Priming, Enhanced Oocyte Recovery, and Delayed Transfer
    NCT04149496
    Condition:   Polycystic Ovary Syndrome
    Intervention:   Combination Product: in vitro maturation of oocytes
    Sponsor:   Bruce Rose, MD
    Recruiting
  • A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (an Autoimmune Disorder That Destructs Platelets, Blood Cells That Help With Clotting, and Can Lead to Easy or Excessive Bruising and Bleeding)
    NCT04188379
    Condition:   Primary Immune Thrombocytopenia
    Interventions:   Biological: efgartigimod;   Other: Placebo
    Sponsor:   argenx BVBA
    Recruiting
  • Biorepository of Biomarkers for Optimization of Microvascular Treatment of Lymphedema
    NCT04123457
    Condition:   Lymphedema
    Intervention:  
    Sponsor:   Mayo Clinic
    Recruiting
  • Globus Pallidus Stimulation to Treat Insomnia
    NCT04116996
    Condition:   Parkinson Disease
    Intervention:   Device: DEEP BRAIN STIMULATION
    Sponsor:   Mayo Clinic
    Recruiting
  • Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine
    NCT04068051
    Condition:   Migraine
    Intervention:   Drug: AXS-07
    Sponsor:   Axsome Therapeutics, Inc.
    Recruiting
  • Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)
    NCT04047810
    Condition:   Chronic Obstructive Pulmonary Disease
    Intervention:   Biological: Mesenchymal Stem Cells
    Sponsor:   Mayo Clinic
    Recruiting
  • Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation
    NCT04046731
    Condition:   Allergy
    Intervention:   Diagnostic Test: Skin Testing
    Sponsor:   Mayo Clinic
    Recruiting
  • Open-Label Safety Study of AXS-05 in Subjects With Depression
    NCT04039022
    Conditions:   Major Depressive Disorder;   Treatment Resistant Depression;   Depression
    Intervention:   Drug: AXS-05
    Sponsor:   Axsome Therapeutics, Inc.
    Recruiting
  • Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty
    NCT04028947
    Condition:   Knee Pain Chronic
    Intervention:   Procedure: Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty
    Sponsor:   Mayo Clinic
    Recruiting
  • Platelet-Rich Fibrin in Intraoral Soft Tissue Regeneration
    NCT04022720
    Condition:   Mucosal Ulceration
    Intervention:   Procedure: Platelet Rich Fibrin Application
    Sponsor:   University of Florida
    Recruiting
  • Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
    NCT04006288
    Condition:   Coronary Artery Disease
    Interventions:   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: ticagrelor;   Drug: aspirin;   Drug: rivaroxaban
    Sponsors:   University of Florida;   Janssen, LP
    Recruiting
  • Early Active Controlled Motion (EACM) Rehabilitation Protocol Post Open Reduction and Internal Fixation (ORIF) of Scaphoid Fractures: A Pilot Study
    NCT03996512
    Condition:   Scaphoid Fixation
    Intervention:   Other: Early Active Controlled Motion (EACM)
    Sponsors:   University of Florida;   Performance Health
    Recruiting
  • Functional Predictive Value of Collective Outcome Measure(s) Status Post Total Hip/Knee Arthroplasty
    NCT03933969
    Conditions:   Joint Arthroplasty;   Knee and Hip
    Intervention:  
    Sponsor:   Mayo Clinic
    Recruiting
  • Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)
    NCT03929120
    Conditions:   Interstitial Lung Disease;   Connective Tissue Diseases
    Intervention:   Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)
    Sponsor:   Mayo Clinic
    Recruiting
  • Development of a Risk Prediction Screening Tool for Opioid-Prescription Injury (STOP Injury) in Older Adults Initiated on Opioids From the Emergency Department
    NCT03836235
    Condition:   Opioid Use
    Intervention:  
    Sponsors:   University of Florida;   National Institute on Aging (NIA);   US Department of Health and Human Services
    Recruiting
  • Assess Screening for Diabetic Retinopathy Using Retinal Camera in Family Medicine Clinic
    NCT03828890
    Condition:   Diabetes Mellitus
    Intervention:   Diagnostic Test: Screening eye exam using Optos technology
    Sponsor:   Mayo Clinic
    Recruiting
  • Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates
    NCT03811873
    Conditions:   Metabolic Bone Disease;   Transplant-Related Disorder;   Secondary Osteoporosis
    Intervention:   Radiation: Thoracic spine X-Ray
    Sponsor:   Mayo Clinic
    Recruiting
  • Treating Acute Pancreatitis With Dabigatran, a Pilot Study
    NCT03807856
    Condition:   Acute Pancreatitis
    Interventions:   Drug: Dabigatran Etexilate Mesylate;   Other: Standard of Care
    Sponsor:   Mayo Clinic
    Recruiting
  • Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
    NCT03774394
    Conditions:   Chronic Kidney Disease (CKD);   Type 2 Diabetes Mellitus (T2DM);   Coronary Artery Disease (CAD)
    Interventions:   Drug: Clopidogrel;   Drug: Clopidogrel active metabolite
    Sponsor:   University of Florida
    Recruiting
  • The Randomized OPTIMAL-ACT Trial
    NCT03772613
    Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Anticoagulant-induced Bleeding;   Coronary Syndrome
    Intervention:   Drug: Unfractionated heparin
    Sponsor:   Mayo Clinic
    Recruiting
  • Stimulation to Enhance Walking Post-SCI
    NCT03702842
    Conditions:   SCI - Spinal Cord Injury;   Incomplete Spinal Cord Injury
    Interventions:   Device: Soterix Medical tsDCS stimulator;   Other: Locomotor training
    Sponsors:   University of Florida;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Brooks Rehabilitation
    Recruiting
  • A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation
    NCT03647917
    Condition:   Skin Aging of Face and Hands
    Intervention:   Biological: Platelet Rich Plasma
    Sponsor:   Mayo Clinic
    Recruiting
  • Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
    NCT03624660
    Condition:   Adenocarcinoma of the Prostate
    Interventions:   Radiation: HR-A;   Radiation: HR-B;   Radiation: HR-C
    Sponsor:   University of Florida
    Recruiting
  • Awake vs. Asleep Craniotomy for Non-eloquent Gliomas
    NCT03621748
    Condition:   Intracranial Glioma
    Interventions:   Procedure: Awake Anesthesia Protocol;   Procedure: Non-awake Anesthesia Protocol
    Sponsor:   Mayo Clinic
    Recruiting
  • Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH
    NCT03611790
    Condition:   Cerebral Vasospasm
    Intervention:   Device: NeVa VS
    Sponsor:   Vesalio
    Recruiting
  • Critical Care and Palliative Care Medicine Together in the ICU
    NCT03520023
    Conditions:   Palliative Care;   Intensive Care Unit;   Hospice
    Intervention:   Other: Palliative Care Consult
    Sponsor:   Mayo Clinic
    Recruiting
  • Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)
    NCT03517852
    Condition:   Peritoneal Carcinomatosis
    Intervention:   Device: Human Intravital Microscopy
    Sponsor:   Mayo Clinic
    Recruiting
  • Mepolizumab for the Treatment of Chronic Spontaneous Urticaria
    NCT03494881
    Condition:   Chronic Spontaneous Urticaria
    Intervention:   Drug: Nucala
    Sponsors:   Mayo Clinic;   GlaxoSmithKline
    Recruiting
  • Incorporating Multidimensional Psychosocial Interventions Improves the Well-being of Individuals With Epilepsy
    NCT03484039
    Conditions:   Epilepsy;   Seizure Disorder
    Interventions:   Behavioral: Medication Adherence;   Behavioral: Seizure Documentation;   Behavioral: Memory Improvement;   Behavioral: Stress Management
    Sponsors:   University of Florida;   Dupont Fund, Jesse Ball;   Florida Blue Foundation;   Riverside Hospital Foundation
    Recruiting
  • Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
    NCT03437044
    Conditions:   Diabetes Mellitus, Type 2;   Coronary Artery Disease
    Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
    Sponsors:   University of Florida;   AstraZeneca
    Recruiting
  • Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids
    NCT03317795
    Conditions:   Heavy Menstrual Bleeding;   Menorrhagia;   Uterine Fibroids
    Interventions:   Drug: Levonorgestrel IUS;   Drug: Tranexamic Acid
    Sponsors:   Shannon K. Laughlin-Tommaso;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting
  • Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
    NCT03096288
    Condition:   Atherosclerotic Cardiovascular Disease
    Interventions:   Drug: Evolocumab;   Other: Placebo
    Sponsors:   University of Florida;   Amgen
    Recruiting
  • Vacuum-Assisted Dressings (V-AD) in the Management of Open Chest Wounds
    NCT02803164
    Condition:   Open Chest Wounds
    Intervention:   Device: Wound Vacuum-assisted dressing
    Sponsor:   Mayo Clinic
    Recruiting
  • Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
    NCT02598349
    Condition:   Pancreatic Cancer
    Interventions:   Radiation: Proton Radiation;   Drug: Capecitabine;   Procedure: Surgical resection;   Behavioral: FACT-Hep questionnaire
    Sponsors:   Proton Collaborative Group;   University of Florida Health
    Recruiting
  • Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques
    NCT02548546
    Condition:   Abdominal Aortic Aneurysm
    Interventions:   Device: ECHO;   Device: ECG-gated MRA
    Sponsor:   Mayo Clinic
    Recruiting
  • Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
    NCT02539160
    Conditions:   Coronary Artery Disease;   Diabetes Mellitus
    Intervention:   Drug: ticagrelor
    Sponsor:   University of Florida
    Recruiting
  • Negative Predictive Value and NIC of Beta-Lactam Antibiotics.
    NCT04126096
    Condition:   Allergy
    Intervention:   Diagnostic Test: Skin Testing
    Sponsor:   Mayo Clinic
    Recruiting
  • Hypersensitivity Reactions During Anesthesia
    NCT04125420
    Condition:   Allergy
    Intervention:  
    Sponsor:   Mayo Clinic
    Recruiting
  • Acupuncture Relief for Chronic Neck Pain
    NCT03859011
    Condition:   Neck Pain, Posterior
    Interventions:   Other: Acupuncture;   Other: Usual Care
    Sponsors:   University of Florida;   Utica College
    Recruiting
  • Study of Cardiac MRI in Patients With Left-Sided Breast Cancer Receiving Radiation Therapy
    NCT02199366
    Condition:   Breast Cancer
    Intervention:   Procedure: Cardiac magnetic resonance (cardiac MRI)
    Sponsors:   University of Florida;   Ocala Royal Dames
    Recruiting
  • Mesenchymal Stem Cell Therapy for Lung Rejection
    NCT02181712
    Conditions:   Lung Transplant Reject;   Bronchiolitis Obliterans
    Interventions:   Biological: Mesenchymal stem cell 0.5;   Biological: Mesenchymal stem cell 1.0
    Sponsor:   Mayo Clinic
    Recruiting
  • Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
    NCT00969111
    Condition:   Prostate Cancer
    Interventions:   Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE;   Radiation: Proton (prostate bed) to 70.2 CGE;   Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE;   Radiation: Proton to 66.6 CGE
    Sponsors:   Proton Collaborative Group;   University of Florida Health
    Recruiting
  • A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
    NCT04144023
    Conditions:   Ductal Breast Carcinoma In Situ;   HER2/Neu Positive
    Interventions:   Biological: Granulocyte-Macrophage Colony-Stimulating Factor;   Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension
    NCT04104490
    Condition:   Pulmonary Arterial Hypertension
    Intervention:  
    Sponsors:   University of Florida;   National Heart, Lung, and Blood Institute (NHLBI);   Mayo Clinic;   Federal University of Health Science of Porto Alegre
    Recruiting
  • Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
    NCT03865212
    Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Metastatic Melanoma;   Metastatic Uveal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Unresectable Melanoma
    Intervention:   Drug: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • Preventing Lymphedema in Axillary Lymph Node Dissection
    NCT03428581
    Condition:   Lymphedema
    Interventions:   Procedure: ALND with ARM +/- LVB;   Procedure: ALND
    Sponsor:   Mayo Clinic
    Recruiting
  • Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
    NCT03106415
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Binimetinib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • TORUS 2 IDE Clinical Study
    NCT04130737
    Condition:   Peripheral Arterial Disease
    Intervention:   Device: TORUS Stent Graft System
    Sponsors:   PQ Bypass, Inc.;   Syntactx
    Recruiting
  • Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
    NCT03947749
    Conditions:   Pain, Chronic;   Prescription Drug Abuse (Not Dependent)
    Intervention:  
    Sponsors:   University of Florida;   Florida Medical Malpractice Joint Underwriting Association
    Recruiting
  • Daily vs. Non-Daily SBRT for NSCLC
    NCT03624907
    Condition:   Non-small Cell Lung Cancer
    Interventions:   Radiation: Daily Stereotactic Body Radiotherapy;   Radiation: Non-Daily Stereotactic Body Radiotherapy
    Sponsor:   University of Florida
    Recruiting
  • Diaphragm Pacing After Spinal Cord Injury
    NCT02556125
    Condition:   Injuries, Spinal Cord
    Intervention:   Device: Diaphragm pacing
    Sponsors:   University of Florida;   Brooks Rehabilitation;   The Craig H. Neilsen Foundation
    Recruiting
  • LIPIDS-P Trial Phase I/II
    NCT03405870
    Conditions:   Sepsis, Severe;   Septic Shock
    Intervention:   Drug: Smoflipid
    Sponsors:   University of Florida;   Fresenius Kabi
    Recruiting
  • Enhancing School-Based Violence Prevention
    NCT04087772
    Condition:   Aggressive Childhood Behavior
    Interventions:   Behavioral: Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH);   Behavioral: Racial/Ethnic Discrimination Interventions (RED)
    Sponsors:   Medical University of South Carolina;   National Institute on Minority Health and Health Disparities (NIMHD)
    Recruiting
  • Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
    NCT03960177
    Condition:   Osteosarcoma
    Intervention:   Drug: Glucarpidase
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting
  • Neoadjuvant Combination Targeted and Immunotherapy for Patients With High-Risk Stage III Melanoma
    NCT03554083
    Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8
    Interventions:   Drug: Atezolizumab;   Drug: Cobimetinib;   Drug: Vemurafenib
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI);   Genentech, Inc.;   Stand Up To Cancer
    Recruiting
  • Renuvion Dermal System for Dermal Resurfacing
    NCT04185909
    Conditions:   Wrinkle;   Rhytides
    Intervention:   Device: Renuvion Dermal System
    Sponsor:   Apyx Medical
    Recruiting
  • Envarsus XR Compared to Immediate Release Tacrolimus
    NCT03979365
    Condition:   Kidney Transplant Recipients
    Interventions:   Drug: Envarsus XR;   Drug: Tacrolimus twice daily
    Sponsors:   Mayo Clinic;   Veloxis Pharmaceuticals
    Recruiting
  • TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol
    NCT03879629
    Condition:   Breast Cancer
    Intervention:   Drug: Carvedilol
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • Shared Decision Making to Improve Goals of Care in the ED
    NCT03833622
    Condition:   Goals
    Intervention:   Other: Shared Decision Aid Assessment
    Sponsor:   Mayo Clinic
    Recruiting
  • Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    NCT03516617
    Conditions:   CCND1 Negative;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   t(11;14) Negative
    Interventions:   Drug: Acalabrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
    NCT03281902
    Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
    NCT03242824
    Condition:   Glioma
    Interventions:   Drug: Fluorine F 18 Fluorodopa;   Radiation: Intensity-Modulated Radiation Therapy;   Procedure: Positron Emission Tomography
    Sponsor:   Mayo Clinic
    Recruiting
  • FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer
    NCT03179904
    Conditions:   HER2 Positive Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: FASN Inhibitor TVB-2640;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Trastuzumab
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • Delineating Swallowing Impairment and Decline in ALS
    NCT02962050
    Condition:   Amyotrophic Lateral Sclerosis
    Interventions:   Procedure: Videofluoroscopic Swallowing Study (VFSS);   Procedure: High Resolution Manometry;   Other: DIGEST;   Other: Penetration Aspiration Scale;   Other: Normalized Residue Ratio Scale;   Device: Voluntary Peak Cough Flow Testing;   Device: Iowa Oral Performance Instrument;   Drug: Capsaicin Challenge;   Device: Pulmonary Function Testing;   Other: Eating Assessment Tool 10;   Other: The Center for Neurologic Study Bulbar Function Scale
    Sponsors:   University of Florida;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting
  • Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    NCT02312245
    Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Topotecan Hydrochloride
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
    NCT01415882
    Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI);   Janssen Scientific Affairs, LLC
    Recruiting
  • The CO2RE® System for Vulvar Lichen Sclerosus
    NCT04148651
    Condition:   Vulvar Lichen Sclerosus
    Intervention:   Device: The CO2RE® System
    Sponsor:   Candela Corporation
    Recruiting
  • Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
    NCT00670358
    Condition:   Lymphoma
    Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
    NCT01871766
    Condition:   Rhabdomyosarcoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Procedure: Surgical Resection;   Procedure: Radiation;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Myeloid Growth Factor;   Procedure: Lymph Node Sampling;   Drug: Irinotecan;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Drug: Doxorubicin;   Drug: Dexrazoxane;   Drug: ^1^1C-methionine
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting
  • pRESET for Occlusive Stroke Treatment
    NCT03994822
    Conditions:   Brain Diseases;   Cardiovascular Diseases;   Central Nervous System Diseases;   Cerebrovascular Disorders;   Ischemia;   Nervous System Diseases;   Pathologic Processes;   Stroke, Ischemic;   Stroke, Acute;   Vascular Diseases
    Interventions:   Device: Mechanical Thrombectomy using the pRESET Thrombectomy device;   Device: Mechanical Thrombectomy using the Solitaire Revascularization Device
    Sponsor:   phenox Inc.
    Recruiting
  • Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
    NCT03464916
    Condition:   Relapsed or Refractory Multiple Myeloma
    Intervention:   Biological: CAR2 Anti-CD38 A2 CAR-T Cells
    Sponsor:   Sorrento Therapeutics, Inc.
    Recruiting
  • To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Type 2 Diabetes.
    NCT04155645
    Conditions:   Dyslipidemia;   Type 2 Diabetes
    Interventions:   Drug: AZD8233 subcutaneous injection;   Drug: Placebo
    Sponsors:   AstraZeneca;   Parexel
    Recruiting
  • A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer
    NCT03200704
    Conditions:   Breast Cancer;   Lymph Node Mapping;   Sentinel Lymph Node Biopsy
    Intervention:   Combination Product: IC2000 and SPY-PHI
    Sponsor:   Novadaq Technologies ULC, now a part of Stryker
    Recruiting
  • P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
    NCT03077243
    Conditions:   Carcinoma, Squamous Cell;   Head and Neck Neoplasms;   Oropharyngeal Neoplasms
    Interventions:   Radiation: Intensity Modulated Radiotherapy (IMRT) - deintensified;   Radiation: Intensity Modulated Radiotherapy (IMRT) - standard;   Drug: Cisplatin (or alternative) - deintensified;   Drug: Cisplatin (or alternative) - standard;   Procedure: Assessment for surgical evaluation
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting
  • Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma
    NCT02560623
    Condition:   Barrett's Esophagus
    Intervention:   Device: Sponge capsule
    Sponsors:   Mayo Clinic;   Exact Sciences Corporation
    Recruiting
  • AMPLATZER PFO Occluder Post Approval Study
    NCT03309332
    Conditions:   Stroke;   Patent Foramen Ovale
    Intervention:   Device: AMPLATZER™ PFO Occluder
    Sponsor:   Abbott Medical Devices
    Recruiting
  • Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
    NCT04167696
    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Biological: CYAD-02;   Drug: ENDOXAN;   Drug: Fludara
    Sponsor:   Celyad (formerly named Cardio3 BioSciences)
    Recruiting
  • Evaluation of A Marketed Silicone Hydrogel Spherical Lens Used for Monovision Correction of Presbyopia
    NCT04073186
    Condition:   Visual Acuity
    Intervention:   Device: ACUVUE® OASYS with Transitions™
    Sponsor:   Johnson & Johnson Vision Care, Inc.
    Recruiting
  • A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
    NCT03761095
    Condition:   Leiomyosarcoma
    Interventions:   Drug: PTC596;   Drug: Dacarbazine
    Sponsor:   PTC Therapeutics
    Recruiting
  • Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
    NCT03624517
    Conditions:   Esophageal Varices;   Liver Cirrhoses;   Bleeding Esophageal Varices;   Upper Gastrointestinal Bleeding
    Intervention:   Drug: Octreotide
    Sponsors:   Medical University of South Carolina;   Ohio State University;   University of Texas Southwestern Medical Center;   University of Florida Health
    Recruiting
  • Coordinating Center: Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy
    NCT03459339
    Condition:   Barrett Esophagus
    Intervention:   Device: Tethered Capsule Endomicroscopy (TCE)
    Sponsors:   Massachusetts General Hospital;   Columbia University;   Mayo Clinic;   Kansas City Veteran Affairs Medical Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting
  • DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
    NCT02772003
    Conditions:   Chronic Hepatitis;   Hepatitis C Infection
    Interventions:   Biological: DNA Plasmid Encoding Interleukin-12 INO-9012;   Biological: Electroporation-Mediated Plasmid DNA Vaccine Therapy;   Biological: HCV DNA Vaccine INO-8000;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   National Cancer Institute (NCI);   Inovio Pharmaceuticals
    Recruiting
  • Efficacy and Safety of UGN-101 in Recurrent Patients
    NCT04006691
    Conditions:   Carcinoma;   Transitional Cell Carcinoma;   Transitional Cell Cancer of the Renal Pelvis and Ureter
    Intervention:   Drug: UGN-101 instillations
    Sponsor:   UroGen Pharma Ltd.
    Recruiting
  • Pursuit: Real World Use of the Eclipse System
    NCT03940573
    Condition:   Fecal Incontinence
    Intervention:   Device: Eclipse Insert
    Sponsor:   Pelvalon, Inc.
    Recruiting
  • Palbociclib in Real World Practice
    NCT03280303
    Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
    Intervention:   Other: non-interventional
    Sponsor:   Pfizer
    Recruiting
  • Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    NCT03499353
    Condition:   Early Breast Cancer
    Intervention:   Drug: TALAZOPARIB
    Sponsor:   Pfizer
    Recruiting
  • A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
    NCT03518034
    Conditions:   Hypogonadism;   Cardiovascular Diseases
    Interventions:   Drug: Testosterone;   Drug: Placebo
    Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
    Recruiting
  • Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
    NCT03473223
    Condition:   Acute Coronary Syndrome
    Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
    Sponsor:   CSL Behring
    Recruiting
  • Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
    NCT00632853
    Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
    NCT03814187
    Conditions:   ASCVD;   Elevated Cholesterol;   Heterozygous Familial Hypercholesterolemia;   Homozygous Familial Hypercholesterolemia
    Intervention:   Drug: Inclisiran Sodium
    Sponsor:   The Medicines Company
    Recruiting
  • Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of PSVT. NODE-302
    NCT03635996
    Condition:   Paroxysmal Supraventricular Tachycardia
    Intervention:   Drug: Etripamil NS 70 mg
    Sponsors:   Milestone Pharmaceuticals Inc.;   Medpace, Inc.
    Recruiting
  • Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
    NCT03574597
    Conditions:   Overweight;   Obesity
    Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
    Sponsor:   Novo Nordisk A/S
    Recruiting
  • Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301
    NCT03464019
    Condition:   Paroxysmal Supraventricular Tachycardia
    Interventions:   Drug: Etripamil;   Drug: Placebo;   Device: Aptar Pharma Nasal Spray
    Sponsors:   Milestone Pharmaceuticals Inc.;   Medpace, Inc.
    Recruiting
  • Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
    NCT03439254
    Conditions:   Compensated Cirrhosis;   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Obeticholic acid (10 mg);   Drug: Obeticholic acid (10 mg to 25 mg);   Drug: Placebo
    Sponsor:   Intercept Pharmaceuticals
    Recruiting
  • Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
    NCT02993406
    Conditions:   Cardiovascular Diseases;   Statin Adverse Reaction
    Interventions:   Drug: Bempedoic acid 180 mg tablet;   Drug: Matching placebo tablet
    Sponsors:   Esperion Therapeutics;   The Cleveland Clinic
    Recruiting
  • Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
    NCT02793583
    Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
    Sponsor:   TG Therapeutics, Inc.
    Recruiting
  • Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
    NCT02630316
    Conditions:   Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
    Interventions:   Drug: Inhaled Treprostinil;   Drug: Placebo
    Sponsor:   United Therapeutics
    Recruiting
  • Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
    NCT02179086
    Conditions:   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
    Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: photon beam radiation therapy;   Radiation: proton beam radiation therapy;   Drug: temozolomide;   Other: laboratory biomarker analysis
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
    NCT02089217
    Condition:   Carotid Stenosis
    Interventions:   Procedure: Carotid endarterectomy (CEA);   Device: Carotid Stenting (CAS);   Other: Intensive Medical Management - no CEA;   Other: Intensive Medical Management - no CAS
    Sponsors:   Thomas G. Brott, M.D.;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting
  • Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
    NCT03585270
    Condition:   Aneurysmal Subarachnoid Hemorrhage
    Interventions:   Drug: Clazosentan;   Drug: Placebo
    Sponsor:   Idorsia Pharmaceuticals Ltd.
    Recruiting
  • A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
    NCT03561220
    Condition:   Prostate Cancer
    Interventions:   Radiation: Standard of Care IMRT (Photon);   Radiation: Standard of Care Proton Therapy;   Radiation: Proton Arm 1: Standard Proton Therapy;   Radiation: Proton Arm 2: Hypofractionated Proton Therapy
    Sponsors:   University of Florida;   Patient-Centered Outcomes Research Institute
    Recruiting
  • A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery
    NCT03689244
    Condition:   Chronic Thromboembolic Pulmonary Hypertension
    Interventions:   Drug: Selexipag;   Drug: Placebo
    Sponsor:   Actelion
    Recruiting
  • Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49
    NCT04142242
    Condition:   Meningococcal Infection (Healthy Volunteers)
    Interventions:   Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine;   Other: Blood sample
    Sponsor:   Sanofi Pasteur, a Sanofi Company
    Recruiting
  • A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
    NCT03431350
    Condition:   Prostatic Neoplasms, Castration-Resistant
    Interventions:   Drug: Niraparib 200 mg;   Drug: JNJ-63723283 240 mg;   Drug: JNJ-63723283 480 mg;   Drug: Abiraterone Acetate;   Drug: Prednisone
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
    NCT04053634
    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Biological: Benralizumab;   Biological: Placebo
    Sponsor:   AstraZeneca
    Recruiting
  • A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
    NCT03882970
    Condition:   Type 2 Diabetes Mellitus
    Interventions:   Drug: Tirzepatide;   Drug: Insulin Degludec
    Sponsor:   Eli Lilly and Company
    Recruiting
  • Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
    NCT03872401
    Condition:   Coronary Heart Disease (CHD)
    Interventions:   Drug: Evolocumab;   Drug: Placebo
    Sponsor:   Amgen
    Recruiting
  • NBP in Adult Patients With Acute Ischemic Stroke (AIS)
    NCT02905565
    Condition:   AIS
    Interventions:   Drug: NBP Softgel Capsules;   Drug: Placebo
    Sponsor:   CSPC-NBP Pharmaceutical Co., Ltd.
    Recruiting
  • To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine
    NCT03777059
    Condition:   Episodic Migraine
    Interventions:   Drug: Atogepant 30 mg;   Drug: Atogepant 60 mg;   Drug: Placebo;   Drug: Atogepant 10 mg
    Sponsor:   Allergan
    Recruiting
  • A Study of Apalutamide in Participants With High‑Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
    NCT03767244
    Condition:   Prostatic Neoplasms
    Interventions:   Drug: Apalutamide;   Drug: Androgen Deprivation Therapy (ADT);   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
    NCT03689712
    Condition:   Oral Mucositis
    Interventions:   Drug: GC4419;   Drug: Placebo
    Sponsor:   Galera Therapeutics, Inc.
    Recruiting
  • An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
    NCT03599622
    Conditions:   Granulomatous Colitis;   Crohn's Disease;   Crohn's Enteritis;   Granulomatous Enteritis
    Interventions:   Drug: BMS-986165;   Other: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
    NCT03561090
    Condition:   Gastroesophageal Reflux Disease (GERD)
    Interventions:   Drug: IW-3718;   Drug: placebo
    Sponsor:   Ironwood Pharmaceuticals, Inc.
    Recruiting
  • Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
    NCT03521934
    Condition:   Heart Failure-Type 2 Diabetes Mellitus
    Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
    Sponsor:   Sanofi
    Recruiting
  • QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
    NCT03510897
    Condition:   Cardiac Surgery
    Interventions:   Drug: QPI-1002;   Drug: Placebo
    Sponsor:   Quark Pharmaceuticals
    Recruiting
  • A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD
    NCT03496623
    Conditions:   Pulmonary Hypertension;   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Inhaled treprostinil solution;   Drug: Placebo solution
    Sponsor:   United Therapeutics
    Recruiting
  • Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
    NCT03417388
    Condition:   Coronary Artery Disease
    Interventions:   Drug: High dose potent statin;   Drug: ACE-I (lisinopril) or ARB (losartan);   Drug: Aspirin;   Behavioral: Lifestyle Counseling;   Behavioral: Quality of Life Questionnaires
    Sponsors:   University of Florida;   United States Department of Defense
    Recruiting
  • Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF‑06700841 In Subjects With Moderate To Severe Crohn's Disease
    NCT03395184
    Condition:   Crohn's Disease
    Interventions:   Drug: Placebo PF-06651600;   Drug: Placebo PF-06700841;   Drug: PF-06651600;   Drug: PF-06700841
    Sponsor:   Pfizer
    Recruiting
  • Hemodynamic-GUIDEd Management of Heart Failure
    NCT03387813
    Conditions:   Heart Failure;   Heart Failure, Systolic;   Heart Failure, Diastolic;   Heart Failure NYHA Class II;   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV;   Heart Failure,Congestive;   Heart Failure With Reduced Ejection Fraction;   Heart Failure With Normal Ejection Fraction;   Heart Failure; With Decompensation
    Intervention:   Device: CardioMEMS™ HF System
    Sponsor:   Abbott Medical Devices
    Recruiting
  • A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
    NCT03383146
    Conditions:   Gastroparesis;   Diabetes Mellitus
    Interventions:   Drug: Relamorelin;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • SPYRAL HTN-ON MED Study
    NCT02439775
    Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
    Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
    Sponsor:   Medtronic Vascular
    Recruiting
  • DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
    NCT03115333
    Conditions:   Gliosarcoma;   Recurrent Glioblastoma
    Intervention:   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
    NCT03071692
    Conditions:   Type2 Diabetes;   Dyslipidemia
    Interventions:   Drug: K-877;   Drug: Placebo
    Sponsors:   Kowa Research Institute, Inc.;   Brigham and Women's Hospital
    Recruiting
  • EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
    NCT03057977
    Condition:   Heart Failure
    Interventions:   Drug: Empagliflozin;   Drug: Placebo
    Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
    Recruiting
  • EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
    NCT03057951
    Condition:   Heart Failure
    Interventions:   Drug: Empagliflozin;   Drug: Placebo
    Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
    Recruiting
  • Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
    NCT02876835
    Condition:   Anaemia
    Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
    Sponsor:   GlaxoSmithKline
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
    NCT02403323
    Condition:   Crohn Disease
    Intervention:   Drug: Etrolizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
    NCT02394028
    Condition:   Crohn Disease
    Interventions:   Drug: Etrolizumab;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Dimethyl Fumarate (DMF) Observational Study
    NCT02047097
    Condition:   Multiple Sclerosis
    Intervention:   Drug: dimethyl fumarate
    Sponsor:   Biogen
    Recruiting
  • Connect® MDS/AML Disease Registry
    NCT01688011
    Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
    Intervention:  
    Sponsor:   Celgene
    Recruiting
  • Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
    NCT00887146
    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment Center (EORTC);   Canadian Cancer Trials Group
    Recruiting
  • Psoriasis Longitudinal Assessment and Registry (PSOLAR)
    NCT00508547
    Conditions:   Psoriasis;   Arthritis, Psoriatic
    Interventions:   Biological: Ustekinumab;   Biological: Biological therapies other than infliximab, ustekinumab and guselkumab;   Drug: Conventional systemic agents;   Biological: Infliximab;   Biological: Guselkumab
    Sponsor:   Janssen Scientific Affairs, LLC
    Recruiting
  • Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
    NCT03895437
    Condition:   Diabetes Mellitus, Type 1
    Interventions:   Biological: TOL-3021;   Other: TOL-3021 Placebo
    Sponsor:   Tolerion, Inc.
    Recruiting
  • Longitudinal Early-onset Alzheimer's Disease Study Protocol
    NCT03507257
    Conditions:   Early Onset Alzheimer Disease;   Alzheimer Disease;   Mild Cognitive Impairment
    Interventions:   Drug: Flortaucipir;   Drug: Florbetaben
    Sponsors:   Liana Apostolova;   Alzheimer's Therapeutic Research Institute;   National Institute on Aging (NIA);   Alzheimer's Association
    Recruiting
  • Extravascular ICD Pivotal Study
    NCT04060680
    Conditions:   Tachycardia;   Ventricular Arrythmia
    Intervention:   Device: Defibrillation
    Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
    Recruiting
  • PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
    NCT02730312
    Conditions:   Acute Myelogenous Leukemia;   B-cell Acute Lymphoblastic Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Chronic Myeloid Leukemia, Blast Crisis
    Intervention:   Biological: XmAb14045
    Sponsors:   Xencor, Inc.;   ICON Clinical Research
    Recruiting
  • Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
    NCT03642210
    Condition:   Menorrhagia
    Intervention:   Combination Product: Levonorgestrel 52 mg intrauterine system
    Sponsor:   Medicines360
    Recruiting
  • Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome
    NCT03951077
    Condition:   Polycystic Ovary Syndrome
    Interventions:   Drug: Elagolix;   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting
  • Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
    NCT02273362
    Conditions:   Cirrhosis;   Hepatocellular Carcinoma
    Interventions:   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
    NCT03572634
    Conditions:   Chronic Lymphocytic Leukemia;   CLL;   SLL;   Small Lymphocytic Lymphoma
    Interventions:   Drug: TP-0903;   Combination Product: TP-0903 and ibrutinib combination therapy
    Sponsor:   Tolero Pharmaceuticals, Inc.
    Recruiting
  • Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
    NCT03206450
    Conditions:   Cancer Survivor;   Osteosarcoma
    Interventions:   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
    NCT03002805
    Condition:   Sarcoma
    Intervention:   Drug: CBT-1®
    Sponsor:   CBA Research
    Recruiting
  • Study of DCC-3014 in Patients With Advanced Tumors
    NCT03069469
    Conditions:   Advanced Malignant Neoplasm;   Tenosynovial Giant Cell Tumor, Diffuse
    Intervention:   Drug: DCC-3014
    Sponsor:   Deciphera Pharmaceuticals LLC
    Recruiting
  • A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
    NCT03129139
    Conditions:   Advanced Cancer;   Gastric Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer Metastatic;   Colo-rectal Cancer;   Solid Tumor;   Solid Carcinoma;   Solid Carcinoma of Stomach;   Cancer of Stomach
    Intervention:   Drug: Minnelide™Capsules
    Sponsors:   Minneamrita Therapeutics LLC;   Translational Drug Development
    Recruiting
  • Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
    NCT03903822
    Condition:   Atopic Dermatitis
    Interventions:   Drug: PF-06700841;   Drug: Vehicle (Placebo)
    Sponsor:   Pfizer
    Recruiting
  • OPsumit USers Registry
    NCT02126943
    Condition:   Pulmonary Arterial Hypertension
    Intervention:   Drug: Opsumit (macitentan)
    Sponsor:   Actelion
    Recruiting
  • Cross-Seal Closure Device IDE Trial
    NCT03756558
    Condition:   Vascular Closure
    Intervention:   Device: Cross-Seal System
    Sponsor:   Terumo Medical Corporation
    Recruiting
  • Increasing Lung Transplant Availability Using Normothermic Ex Vivo Lung Perfusion (EVLP) at a Dedicated EVLP Facility
    NCT03641677
    Condition:   Lung Diseases
    Interventions:   Device: Centralized Lung Evaluation System;   Procedure: Lung Transplant
    Sponsor:   Lung Bioengineering Inc.
    Recruiting
  • Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
    NCT03533257
    Condition:   Alzheimer Disease
    Interventions:   Drug: AMX0035;   Drug: Placebo
    Sponsors:   Amylyx Pharmaceuticals Inc.;   Alzheimer’s Drug Discovery Foundation;   Alzheimer's Association
    Recruiting
  • Treatment With Intent to Generate Endovascular Reperfusion
    NCT03474549
    Condition:   Ischemic Stroke
    Intervention:   Device: Tigertriever revascularization device
    Sponsor:   Rapid Medical
    Recruiting
  • Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491
    NCT03447990
    Conditions:   Dilated Cardiomyopathy;   Heart Failure With Reduced Ejection Fraction
    Intervention:   Drug: MYK-491
    Sponsor:   MyoKardia, Inc.
    Recruiting
  • Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
    NCT03334409
    Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v7;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Ascorbic Acid;   Drug: Pazopanib Hydrochloride
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting
  • A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients
    NCT03150420
    Condition:   Calciphylaxis
    Interventions:   Drug: Sodium Thiosulfate;   Drug: Placebo-Normal Saline
    Sponsor:   Hope Pharmaceuticals
    Recruiting
  • INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
    NCT03037164
    Condition:   Anemia
    Interventions:   Device: INTERCEPT Blood System for Red Blood Cells;   Device: Conventional (Control)
    Sponsor:   Cerus Corporation
    Recruiting
  • R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
    NCT02628405
    Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting
  • Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
    NCT03934216
    Condition:   Ulcerative Colitis
    Interventions:   Drug: BMS-986165;   Drug: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy
    NCT03837327
    Conditions:   Adnexal Mass;   Ovarian Cancer;   Pelvic Mass
    Intervention:  
    Sponsor:   Venn Biosciences Corporation
    Recruiting
  • Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
    NCT03654313
    Conditions:   Atherosclerosis;   Cardiovascular Disease
    Interventions:   Biological: MEDI6570;   Biological: Placebo;   Biological: Part B Placebo
    Sponsor:   MedImmune LLC
    Recruiting
  • A Study of a Personalized Neoantigen Cancer Vaccine
    NCT03639714
    Conditions:   Non Small Cell Lung Cancer;   Colorectal Cancer;   Gastroesophageal Adenocarcinoma;   Urothelial Carcinoma
    Interventions:   Biological: GRT-C901;   Biological: GRT-R902;   Biological: nivolumab;   Biological: ipilimumab
    Sponsors:   Gritstone Oncology, Inc.;   Bristol-Myers Squibb
    Recruiting
  • MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
    NCT03489525
    Condition:   Relapsed/Refractory Multiple Myeloma
    Interventions:   Biological: Dose Escalation, MEDI2228, ADC (antibody drug conjugate);   Biological: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
    Sponsor:   MedImmune LLC
    Recruiting
  • The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
    NCT03487913
    Condition:   Autosomal Dominant Polycystic Kidney Disease
    Intervention:   Drug: Lixivaptan
    Sponsor:   Palladio Biosciences
    Recruiting
  • Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
    NCT03266692
    Conditions:   Multiple Myeloma;   Multiple Myeloma in Relapse;   Refractory Multiple Myeloma
    Interventions:   Biological: ACTR087;   Biological: SEA-BCMA
    Sponsors:   Unum Therapeutics Inc.;   Seattle Genetics, Inc.
    Recruiting
  • Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
    NCT03230318
    Conditions:   Intrahepatic Cholangiocarcinoma;   Combined Hepatocellular and Cholangiocarcinoma
    Intervention:   Drug: derazantinib
    Sponsor:   Basilea Pharmaceutica
    Recruiting
  • Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
    NCT01617161
    Condition:   Prostate Cancer
    Interventions:   Radiation: Proton Beam Therapy;   Radiation: Intensity Modulated Radiation Therapy
    Sponsors:   Massachusetts General Hospital;   University of Pennsylvania;   National Cancer Institute (NCI);   Northwestern Medicine Chicago Proton Center;   ProCure Proton Therapy Center;   Washington University School of Medicine;   University of Washington;   Rutgers Cancer Institute of New Jersey;   Provision Center for Proton Therapy;   Mayo Clinic;   University of Maryland, College Park;   University Hospitals Cleveland Medical Center;   University of Florida Proton Therapy Institute
    Recruiting
  • A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy
    NCT03054870
    Condition:   Lung Structure Determination
    Interventions:   Drug: Xe-133;   Drug: Technegas
    Sponsor:   Cyclomedica Australia PTY Limited
    Recruiting
  • Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
    NCT03030222
    Condition:   Heart Failure
    Interventions:   Drug: Empagliflozin 10Mg Tab;   Drug: Placebo Oral Tablet
    Sponsor:   Saint Luke's Health System
    Recruiting
  • Trident II Tritanium Acetabular Shell Outcomes Study
    NCT02999009
    Condition:   Arthroplasty, Replacement, Hip
    Intervention:   Device: Trident II Tritanium Acetabular Shell
    Sponsor:   Stryker Orthopaedics
    Recruiting
  • Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)
    NCT02962895
    Condition:   Primary Sjogren's Syndrome
    Interventions:   Biological: VAY736;   Other: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)
    NCT02952508
    Conditions:   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma;   Marginal Zone Lymphoma;   Mantle-Cell Lymphoma;   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: CLR 131 single dose;   Drug: CLR 131 multiple dose
    Sponsor:   Cellectar Biosciences, Inc.
    Recruiting
  • Eliminating Surgery After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer
    NCT02945579
    Conditions:   Estrogen Receptor Negative;   HER2 Positive Breast Carcinoma;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
    Interventions:   Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Whole Breast Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies
    NCT02924402
    Conditions:   B-cell Non-Hodgkins Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Intervention:   Biological: XmAb13676
    Sponsors:   Xencor, Inc.;   Chiltern International Inc.
    Recruiting
  • Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
    NCT02807272
    Condition:   Leukemia, Myelomonocytic, Chronic
    Intervention:   Drug: Tipifarnib
    Sponsor:   Kura Oncology, Inc.
    Recruiting
  • Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
    NCT02633059
    Conditions:   Loss of Chromosome 17p;   Recurrent Plasma Cell Myeloma
    Interventions:   Drug: Dexamethasone;   Drug: Idasanutlin;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
    NCT02361346
    Conditions:   Non-Hodgkin's B-cell Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell;   Small Lymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Blood Cancer;   Hematological Malignancy
    Interventions:   Drug: MT-3724 Phase 1;   Drug: MT-3724 Phase 2
    Sponsor:   Molecular Templates, Inc.
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
    NCT04041284
    Conditions:   Migraine;   Major Depressive Disorder
    Interventions:   Drug: Fremanezumab;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Recruiting
  • A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
    NCT04032704
    Conditions:   Small Cell Lung Cancer;   Non-small Cell Lung Cancer, Squamous;   Non-small Cell Lung Cancer, Non-squamous;   Head and Neck Squamous Cell Carcinoma;   Esophageal Squamous Cell Carcinoma;   Gastric Adenocarcinoma;   Gastroesophageal Junction Adenocarcinoma
    Intervention:   Drug: ladiratuzumab vedotin
    Sponsor:   Seattle Genetics, Inc.
    Recruiting
  • Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
    NCT03980730
    Condition:   Alzheimer Disease
    Interventions:   Drug: Azeliragon;   Drug: Placebo
    Sponsor:   vTv Therapeutics
    Recruiting
  • A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
    NCT03955939
    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: LY3295668 Erbumine;   Drug: Endocrine therapy;   Drug: Midazolam
    Sponsor:   Eli Lilly and Company
    Recruiting
  • Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression
    NCT03872206
    Condition:   Advanced Cancers Associated With Mesothelin Expression
    Intervention:   Biological: HPN536
    Sponsor:   Harpoon Therapeutics
    Recruiting
  • A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
    NCT03859427
    Condition:   Relapsed or Refractory Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Amgen
    Recruiting
  • Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section
    NCT03853694
    Conditions:   Elective Cesarean Section;   Pain Management
    Interventions:   Drug: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen;   Drug: 150 mcg Duramorph + multi-modal pain regimen;   Drug: Exparel TAP + multi-modal pain regimen
    Sponsor:   Pacira Pharmaceuticals, Inc
    Recruiting
  • Florida Pancreas Collaborative Next Generation Biobank
    NCT03851133
    Conditions:   Pancreatic Cancer;   Cancer Cachexia
    Interventions:   Other: Blood Sample Collection;   Other: Tumor Sample collection;   Other: Data Collection
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting
  • Triathlon® Partial Knee Replacement (PKR) Outcomes Study
    NCT00966979
    Condition:   Arthroplasty, Replacement, Knee
    Intervention:   Device: Triathlon PKR
    Sponsor:   Stryker Orthopaedics
    Recruiting
  • HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
    NCT03759379
    Conditions:   Amyloidosis, Hereditary;   Transthyretin Amyloidosis
    Interventions:   Drug: Patisiran;   Drug: Vutrisiran (ALN-TTRSC02)
    Sponsor:   Alnylam Pharmaceuticals
    Recruiting
  • Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
    NCT03757949
    Condition:   Bladder Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Dietary Supplement: Nutritional Intervention;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Dominantly Inherited Alzheimer Network (DIAN)
    NCT00869817
    Condition:   Alzheimer's Disease
    Intervention:  
    Sponsors:   Washington University School of Medicine;   National Institute on Aging (NIA)
    Recruiting
  • A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
    NCT03649971
    Condition:   Adenomatous Polyposis Coli
    Interventions:   Drug: Guselkumab;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
    NCT03593681
    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Ovarian Neoplasms;   Ovary Cancer;   Fallopian Tube Neoplasms;   Fallopian Tube Adenocarcinoma;   High Grade Serous Carcinoma;   Peritoneal Carcinoma;   Peritoneal Neoplasms;   Adnexal Mass;   Ovarian Diseases
    Intervention:   Device: Hysteroscopic cell sampling of the fallopian tube
    Sponsors:   nVision Medical;   Boston Scientific Corporation
    Recruiting
  • The SHUNT-V Study for Varices
    NCT03583996
    Condition:   Chronic Liver Disease
    Intervention:   Combination Product: HepQuant SHUNT Liver Diagnostic Test
    Sponsor:   HepQuant, LLC
    Recruiting
  • A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
    NCT03539744
    Condition:   Multiple Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Venetoclax
    Sponsor:   AbbVie
    Recruiting
  • A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
    NCT03412565
    Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Carfilzomib
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
    NCT03288480
    Condition:   Multiple Myeloma
    Intervention:   Drug: PT-112
    Sponsor:   Phosplatin Therapeutics
    Recruiting
  • A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma
    NCT03287908
    Condition:   Relapsed/Refractory Multiple Myeloma
    Intervention:   Drug: AMG 701
    Sponsor:   Amgen
    Recruiting
  • Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
    NCT01696721
    Condition:   Pediatric Patients Treated With Radiation Therapy
    Intervention:   Other: No intervention
    Sponsor:   Massachusetts General Hospital
    Recruiting
  • A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
    NCT03215706
    Condition:   Non-Small Cell Lung Cancer
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Cisplatin
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
    NCT03194542
    Conditions:   Primary Myelofibrosis;   Anemia
    Intervention:   Drug: Luspatercept
    Sponsor:   Celgene
    Recruiting
  • Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
    NCT03080883
    Conditions:   Cerebral Vein Thrombosis;   Deep Vein Thrombosis;   Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Pulmonary Embolism;   Splanchnic Vein Thrombosis
    Intervention:   Drug: Apixaban
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
    NCT03038672
    Conditions:   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Burkitt-Like Lymphoma With 11q Aberration;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Mucocutaneous Ulcer;   High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Human Herpesvirus 8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Biological: Nivolumab;   Drug: Varlilumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
    NCT03030235
    Condition:   Chronic Heart Failure With Preserved Systolic Function
    Interventions:   Drug: Dapagliflozin 10Mg Oral Tablet;   Drug: Dapagliflozin matching placebo
    Sponsor:   Saint Luke's Health System
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC